SCHEMBL3602364

SCHEMBL3602364

CCC(C(=O)O)c1ccc(OC2CCN(CC(O)(c3cn(Cc4ccccc4)c4cc([N+](=O)[O-])ccc34)C(F)(F)F)CC2)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.37
AKR1C2 P52895 3/20 0.37
CCR5 P51681 1/20 0.35
MAPK1 P28482 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
TACR1 P25103 1/20 0.33
CYP2D6 P10635 1/20 0.33
KCNJ1 P48048 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
PGR P06401 1/20 0.33
CHRM2 P08172 1/20 0.33
ABCB1 P08183 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602359 1.00 AKR1C3 (0.37) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3585737 0.97 AKR1C3 (0.37) AKR1C3AKR1C2CCR5MAPK1ALDH1A1
SCHEMBL3585732 0.97 AKR1C3 (0.37) AKR1C3AKR1C2CCR5MAPK1ALDH1A1
SCHEMBL3585512 0.96 AKR1C3 (0.36) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3586832 0.96 AKR1C3 (0.36) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3586837 0.96 AKR1C3 (0.36) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3585504 0.96 AKR1C3 (0.36) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3600419 0.95 AKR1C3 (0.37) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3600423 0.95 AKR1C3 (0.37) AKR1C3AKR1C2CCR5MAPK1TP53
SCHEMBL3599457 0.94 AKR1C3 (0.36) AKR1C3AKR1C2CCR5MAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 AKR1C3 278/4885AKR1C2 614/4885CCR5 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.